Ukrainian Pharma: challenges and opportunities Pharmaceutical Industry Review, special issue, December 2022
in Ukraine due to close cooperation of pharma producers and importers, officials from the Ministry of Health of Ukraine, distributors and pharmacies. It might seem to be complicated during the war, however Farmak’s team managed to organize steady work of the company. In May the new production facility for medicines manufacturing in nebulas was commissioned. The company • received EUR 20 M loan from the European Bank for Reconstruction and Development,
• found alternative supply chains and continued medicines export to international markets,
• invested in new production facilities in suburbs of Barcelona,
• launched 11 new medicines for Ukrainian market and plan to launch 6 more till 2022 year end,
• proved to be a reliable partner able to ensure supply of own products to both local and international markets.
Farmak’s CEO Volodymyr Kostyuk analyzed achievements and future prospects of Ukrainian pharma and revealed a large number of opportunities to strengthen mutually beneficial cooperation between Ukrainian pharma producers and international partners. In his opinion there are the following advantages for mutual work with Ukraine in the field of medicines manufacturing: 1. Exceptional geographic location of Ukraine which might enable:
• Reduction of supply chain – Ukraine may become API and generic medicines supplier for USA and EU markets
• Convenient logistics and diplomatic relations favorable for export extension to MENA region
2. Considerable potential of Ukrainian companies in chemical and pharmaceutical fields which might provide:
50 BACK TO CONTENTS
• Opportunity for API manufacturing in Ukraine, integration in medicine manufacturing and supply chains for EU and USA markets
• Duly equipped industrial parks for manufacturing of chemical and pharmaceutical products
• Human and educational resources in the field of API manufacturing and R&D
3. Considerable amount of manufacturing facilities (there are about 120 pharma companies in Ukraine).
According to UN data about 5.5 M Ukrainian citizens have refugee status – Ukraine may provide them with necessary medicines using availability of excessive manufacturing facilities. There are following options for future co- operation provided mentioned above: • Contract manufacturing of medicines for international pharma companies and transfer of new technologies as well as localization of manufacturing of
innovation medicines (for supply to the markets of EU, Ukraine, Moldova, Georgia, MENA).
• Integration of Ukraine into optimized (shortened in geographical meaning) supply chains by means of API manufacturing for EU and USA.
• Guarantee of uninterrupted supply of generic medicines for EU countries.
• Clinical trials in Ukraine might replace those done on Russian market since now they are sus- pended by majority of interna- tional companies due to sanc- tions against the aggressor country.
In addition, Ukraine developed Renovation Plan for the period until 2032 which contains the paragraph on stimulation of pharma manufacturing that was defined as a priority industry by the state. Thus the Plan envisages a number of stimuli for development of Ukrainian pharma and international cooperation as well as guarantee strong support from the state.
www.promoboz.com
www.promoboz.com |
www.cphem.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
